Skip to content
Top Globe News – Lifestyle
Author:
ELI LILLY AND COMPANY
FDA approves Lilly’s Olumiant (baricitinib) for pediatric patients 12 years of age and older with severe alopecia areata
September 25, 2026
U.S. Food and Drug Administration (FDA) approves Lilly’s Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin injection treatment for adults living with type 2 diabetes
September 24, 2026
Lilly breaks ground in Houston, one of ten U.S. manufacturing sites announced since 2020
September 22, 2026
U.S. FDA approves Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
September 21, 2026
Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health
September 15, 2026
Lilly completes acquisition of AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
September 11, 2026
Lilly to participate in Morgan Stanley 24th Annual Global Healthcare Conference
September 1, 2026
New Phase 3b data on Lilly’s Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity
August 31, 2026
Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market
August 12, 2026
Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress
August 5, 2026
1
2
3
…
6
Next Page
→